Kallyope Stock
Kallyope is a healthcare company focusing on biotechnology business.
Sign up today and learn more about Kallyope Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Kallyope Stock
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology
Investors
Illumina
Funding History
December 2015 | $44.0M |
---|---|
February 2018 | $66.0M |
Management
CEO
Nancy Thornberry
Founder
Tom Maniatis
Founder
Charles Zuker
Press
patents - Apr, 15 2024
Gpr119 and gpr40 agonist combination therapies for gut-brain axis disorderspatents - Apr, 15 2024
gpr40 agonistspatents - Apr, 15 2024
Ampk activatorspatents - Apr, 15 2024
Systems and methods for associating genes with phenotypespatents - Apr, 15 2024
Treatment of headache disorders with nk3 modulators